Nachrichten zur Biogen Aktie

Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter…

Biogen CEO Viehbacher to Boost Investment in New Drugs for ...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up

Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market....…

Biogen expects new Alzheimer’s drug to weigh on 2023 outlook

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do…

Opening Bell: TripAdvisor, Airbnb, Tesla, Biogen, BioCryst

Die US-Inflationsdaten sorgten gestern für eine kleine Berg- und Talfahrt bei den US-Indizes. Am Ende ging der Dow Jones mit…

Opening Bell: Dow Jones startet im Minus; Einzelhandelsumsätze Januar, Biogen, Tripadvisor, Airbnb, Tesla, Biocryst im Fokus

Starke Einzelhandelsumsätze im Januar verunsichern am Mittwoch die Anleger an der Wall Street und drücken die Indizes ins Minus. 30…

Drugmaker Biogen tops 4Q forecasts despite sales slip

Biogen closed 2022 with a better-than-expected fourth quarter, as more cost cutting helped counter sales declines for some key treatments...…

Biogen Q4 Results Top Estimates

Biotechnology company Biogen Inc. reported Wednesday that profit for the fourth quarter surged 50 percent from last year, reflecting lower…

Biogen Q4 Results Top Estimates

WESTON (dpa-AFX) - Biotechnology company Biogen Inc. (BIIB) reported Wednesday that profit for the fourth quarter surged 50 percent from…

Biogen Inc. Q4 Profit Increases, beats estimates

WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced earnings for its fourth quarter that increased from the same period last year…

Biogen’s stock gains after company beats Q4 revenue and earnings expectations

Shares of Biogen Inc. BIIB gained about 1.7% in premarket trading on Wednesday after the company beat revenue and earnings…

Biogen beats Q4 top and bottom line estimates; initiates FY23 outlook

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen earnings beat estimates on boost from muscle disorder drug

...(Reuters) - Biogen Inc beat Wall Street expectations......…

Drugs for Alzheimers, Depression, Are in Focus as Biogen Reports Earnings

The expected rollouts of both drugs this year are vital to the company's future because its remaining offerings face intense…

Airbnb, Coca-Cola, Shopify, and More to Watch

The January consumer price index is out on Tuesday. Plus, earnings from Airbnb, Coca-Cola, Marriott, Biogen, Cisco, Shopify, DoorDash, Hasbro,…

FDA accepts NDA filing by Biogen and Sage for zuranolone

After granting priority review for the application, the FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of…

Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know

Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day....…

Sage Therapeutics: FDA To Review NDA For Zuranolone

WESTON (dpa-AFX) - Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) announced the FDA has accepted the filing of a…

Biogen, Sage Get FDA Priority Review of Zuranolone >BIIB SAGE

Biogen, Sage Get FDA Priority Review of Zuranolone >BIIB SAGE...…

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced…

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day....…

LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN

TOKYO and CAMBRIDGE, Mass., January 29, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen…

Biotech Stocks Facing FDA Decision In February 2023

FOSTER CITY (dpa-AFX) - As we move into the shortest month of the year, lets take a look at some…

Biogen Alzheimers Drug Lecanemab Gets EU Marketing Authorization

Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization...…

Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…

AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nach Biogen und Eisai – diesem Hot-Stock könnte jetzt ein weiterer Durchbruch im Kampf gegen Alzheimer gelingen

Spätestens seit dem Durchbruch von Biogen und dem japanische Entwicklungspartner Eisai mit ihrem Alzheimer-Mittel Leqembi ist klar: Die Alzheimer-Branche befindet…

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session....…

If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today

The stock hasnt been a great investment in recent years, but theres hope for a brighter future....…

Hot-Stock der Woche: Nie mehr verzetteln

Biogen und der japanische Entwicklungspartner Eisai haben zuletzt mit dem Alzheimer-Mittel Leqembi für Furore gesorgt. Die von Rückschlägen gebeutelte Branche…

Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan

Biogens (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimers disease in Japan....…

Eisai and Biogen apply for approval of Alzheimer’s drug in Japan

The two companies hope to gain approval by the end of the year following the U.S. Food and Drug Administrations…

Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know

Biogen Inc. (BIIB) closed at $288.08 in the latest trading session, marking a +1.07% move from the prior day....…

Fewer approvals in 2022 from cautious FDA

After approving an average of 51 drugs per year since 2017, there were only 37 FDA approvals in 2022. It…

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed at $274.72 in the latest trading session, marking a -1.62% move from the prior day....…

Biogen: Einer der Riesengewinner 2023? Aktienanalyse

Kulmbach (www.aktiencheck.de) - Biogen-Aktienanalyse von "Der Aktionär": Martin Weiss, stellvertretender Chefredakteur vom Anlegermagazin "Der Aktionär", nimmt die Biogen-Aktie (ISIN: US09062X1037, WKN:…

Grabar Law Office Investigates Claims on Behalf of Shareholders of Biogen, Inc. (BIIB) After It Agrees to Pay $900 Million for Improper Kickbacks

Philadelphia, Pennsylvania--(Newsfile Corp. - January 9, 2023) - The DOJ has announced that Biogen has agreed to pay $900…

Opening Bell: New York freundlich zum Wochenauftakt; Biogen, Bumble, First Solar, Enphase, Tesla, Alibaba, Netease im Fokus

Die US-Aktienmärkte dürften ihre starke Performance vom Freitag zum Wochenstart gebremst fortsetzen. Gestützt werden die Börsen weiterhin von der Öffnung…

dpa-AFX ProFeed